MEK1/2-ERK Pathway Alterations as a Therapeutic Target in Sporadic Alzheimer’s Disease: A Study in Senescence-Accelerated OXYS Rats. Here, MAP2K1 is linked to early-onset autosomal dominant Alzheimer disease.